what are the tirzepatide medications for Weight Loss - Dual GIP/GLP-1 Guide Users of Zepbound or Mounjaro

Effective April 22, 2026, BPC-157 was removed from Category 2 (the bulks substances list flagged as raising significant safety concerns)

A scintigraphic study in healthy subjects and diabetic patients

Key Takeaways Agonism Profile: Tirzepatide is a dual GLP-1/GIP agonist, while Retatrutide is a "triple agonist" targeting GLP-1, GIP, and Glucagon receptors

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

In this blog, Ill share my personal experience with semaglutide, the challenges I faced, and how it ultimately changed my life

21 Yoshino et al